Quick Answer
Revolution Medicines, Inc. reported Operating Income Loss of -$1.18 billion for the year ending 2025.
- Revolution Medicines, Inc. showed a decrease of -71.5% in Operating Income Loss from 2024 to 2025.
- This data is from Revolution Medicines, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$10.44 million | Q2 2019: -$10.56 million | Q3 2019: -$13.56 million | Q1 2020: -$21.08 million | Q2 2020: -$27.98 million | Q3 2020: -$27.55 million | Q1 2021: -$37.40 million | Q2 2021: -$44.54 million | Q3 2021: -$53.16 million | Q1 2022: -$57.95 million | Q2 2022: -$62.09 million | Q3 2022: -$76.53 million | Q1 2023: -$75.16 million | Q2 2023: -$108.80 million | Q3 2023: -$123.25 million | Q1 2024: -$140.86 million | Q2 2024: -$156.64 million | Q3 2024: -$175.71 million | Q1 2025: -$240.76 million | Q2 2025: -$264.71 million | Q3 2025: -$315.27 million.
- Over the full 8 years of available data (2018 to 2025), Revolution Medicines, Inc.'s Operating Income Loss has declined by 2,831.8%.
- Historical annual values: Fiscal year 2025: -$1.18 billion | Fiscal year 2024: -$689.52 million | Fiscal year 2023: -$487.19 million | Fiscal year 2022: -$258.28 million | Fiscal year 2021: -$188.01 million | Fiscal year 2020: -$110.70 million | Fiscal year 2019: -$54.12 million | Fiscal year 2018: -$40.33 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: